Review of the possibilities of regional intra-arterial chemotherapy in the treatment of squamous cell carcinoma of the nasal cavity and paranasal sinuses

In this literary review analyzed the possibilities of combination therapy in the treatment of locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinuses, compares the frequency and nature of side effects in its different variants, assessed the effectiveness of intra-arterial chemotherapy in comparison with other methods.

Combined treatment with the use of systemic chemotherapy allows not carry out massive surgical operations, but does not improve the long-term results of treatment. Regional intra-arterial chemotherapy has a number of advantages: improves the tumor response to treatment, long-term results, as well as expands the possibilities of organ-preserving treatment performance and, accordingly, improves the quality of life of patients. Another advantage is the possibility of a parallel use of detoxifier, which excludes the toxic effect, which is inherent in systemic chemotherapy. The implementation of this technology in a wide clinical practice is limited by the need for special equipment for interventional radiology and, consequently, the increased cost of treatment. However, the high efficiency of this method in the future is likely to lead to its active implementation in clinical practice.

1. Ock C.Y., Keam B., Kim T.M. et al. Induction chemotherapy in head and neck squamous cell carcinoma of the paranasalsinus and nasal cavity: a role in organ preservation. Korean J Intern Med 2016;31(3):570–8. DOI: 10.3904/kjim.2015.020.

2. Reyes-Gibby C.C., Anderson K.O., Merriman K.W. et al. Survival patterns in squamous cell carcinoma of the head and neck: pain as an independent prognostic factor for survival. J Pain 2014;15(10):1015–22. DOI: 10.1016/j.jpain.2014.07.003.

3. Fernström E., Nyman J., Hammerlid E. et al. Results of preoperative chemoradiotherapy for patients with advanced cancer of the nasal cavity and paranasal sinuses. Acta Otolaryngol 2017;137(12):1292–300. DOI: 10.1080/00016489.2017.1357081.

4. Bristol I.J., Ahamad A., Garden A.S. et al. Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. Int J Radiat Oncol Biol Phys 2007;68(3):719–30. DOI: 10.1016/j.ijrobp.2007.01.032.

5. Dimery I.W., Hong W.K. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85(2):95–111. DOI: 10.1093/jnci/85.2.95.

6. International Nasopharynx Cancer Study Group. Preliminary results of randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (>N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 1996;35(3):463–9. PMID: 8655368.

7. Sanders I.W., Haslet K., Correa P. et al. Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer – a retrospective analysis of toxicity and outcomes. Scottish Med J 2014;59(1): 50–5. DOI: 10.1177/0036933013518153.

8. Lorch J.H., Goloubeva O., Haddad R.I. et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011;12(2):153–9. DOI: 10.1016/S1470-2045(10)70279-5.

9. Kim J.H., Lee Y.S., Chung Y.-S. et al. Treatment outcomes of concurrent chemoradiotherapy for locally advanced sinonasal squamous cell carcinoma: A single-institution study. Acta Otolaryngol 2015;135(11):1189–95. DOI: 10.3109/00016489.2015.1061697.

10. Garavello W., Ciardo A., Spreafico R., Gaini R.M. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006;132(7):762–6. DOI: 10.1001/archotol.132.7.762.

11. Richard J.M., Sancho H., Lepintre Y. et al. Intra-arterial methotrexate chemotherapy and telecobalt therapy in cancer of the oral cavity and oropharynx. Cancer 1974;34:491–6.

12. Robbins K.T., Kumar P., Wong F.C. et al. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck 2000;22(7):687–93. PMID: 11002324.

13. Foote R.L., Kasperbauer J.L., Okuno S.H. et al. A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract. Cancer 2005;103(3):559–68. DOI: 10.1002/cncr.20803.

14. Rabbani A., Hinerman R.W., Schmalfuss I.M. et al. Radiotherapy and concomitant intraarterial cisplatin (RADPLAT) for advanced squamous cell carcinomas of the head and neck. Am J Clin Oncol 2007;30(3):283–6. DOI: 10.1097/01.coc.0000258118.38177.74.

15. Homma А., Sakashita T., Yoshida D. et. al. Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer. Br J Cancer 2013;109:2980–6. DOI: 10.1038/bjc.2013.663.

16. Furusaka T., Asakawa T., Tanaka A., Ikeda M. Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer. Acta Otolaryngol 2012;132(10):1108–14. DOI: 10.3109/00016489.2012.684702.

17. Namon A.J., Panje W.R. Controversy in the management of tumors of the nasal cavity and paranasal sinuses. In: Comprehensive Management of Head and Neck Tumors. 2nd ed. Eds.: S.E. Thawley, W.R. Panje, J.G. Batsakis et al. Philadelphia: WB Saunders, 1999.